Dentsply Sirona acquires Datum Dental, a leading provider of the innovative OSSIX® regenerative solutions portfolio
Dentsply Sirona today announced that it has acquired Datum Dental, Ltd. with its strong OSSIX® biomaterial portfolio. Datum Dental is an Israel-based company, known for its innovative dental regeneration products with the clinically superior proprietary technology GLYMATRIX®. Datum Dental complements Dentsply Sirona’s existing implant dentistry strategy around Ankylos, Astra Tech Implant System, Xive and Atlantis, focusing on established quality and meaningful innovation. In addition, Datum Dental has a strong R&D pipeline with many promising products with differentiated value propositions and Dentsply Sirona has the capacity to further invest in its future development.
Dentsply Sirona acquires Datum Dental, a leading provider of the innovative OSSIX® regenerative solutions portfolio
Charlotte. The acquisition of Datum Dental will open up significant opportunities for Dentsply Sirona within its Implants segment. With a track record of simplifying and developing innovations for regenerative procedures, the OSSIX® portfolio will support the vision to become one of the leaders in the dental regeneration industry. With innovative products driven by the GLYMATRIX® core technology, OSSIX® bio-durable design will ensure long-term predictable and superior results. The OSSIX® dental regeneration products will support and enhance the future of implant dentistry and oral care.
“Datum Dental perfectly fits in our strategy to deliver innovative and meaningful solutions for our customers. The biomaterial sector is an important cornerstone of the future of dentistry. The acquisition is another important step for us to deliver on our purpose to empower dental professionals to provide patients with better dental care and make people smile,” says Gene Dorff, Group Vice President Implants Product Group of Dentsply Sirona.
“We are pleased that the OSSIX® family is becoming part of the market leader in dental. Dentsply Sirona offers us opportunities to work on continued innovation with the strongest R&D team in the industry. Our R&D pipeline will continue to develop new, safe and transformational solutions – that simplify procedures and overcome major deficiencies in existing biomaterial‐based regenerative products,” says Itay Itzhaky, Chief Executive Officer of Datum Dental.
Since 2016, Dentsply Sirona has already been in distribution agreements with Datum Dental. Today, Dentsply Sirona is promoting the full OSSIX® portfolio (OSSIX® Plus, OSSIX® Volumax, and OSSIX™ Bone) in the U.S., Canada, Colombia, France, Belgium, UK-Ireland, Nordics, Poland, Romania, Turkey and Hong Kong.
Clinicians will benefit in the future from OSSIX® products’ being implemented in a broad set of solutions and workflows and Dentsply Sirona’s capacity to invest in the future development. The strong OSSIX® portfolio will be the foundation of the Regenerative portfolio of Dentsply Sirona. The transaction is expected to close in January 2021, following customary approval requirements.
About Datum Dental
Datum Dental is an innovative Israel-based company for dental regeneration products with clinically superior proprietary technology. The company markets its products for dental professionals through its extensive global network of partners in over 40 countries worldwide. The company was founded in 2012, has 50 employees and its headquarters is in Lod, close to Tel Aviv, Israel.
Datum Dental is a leading provider of the innovative OSSIX® regenerative solutions portfolio. Powered by the company’s patented GLYMATRIX® technology, OSSIX® Plus, OSSIX® Volumax, and OSSIX™ Bone are covered by over 100 scientific publications and extensive clinical experience with thousands of clinicians. The company uses its proprietary GLYMATRIX® core technology, a proven process that uses naturally occurring sugar to cross-link collagen biomaterial, for guided bone regeneration (GBR) and guided tissue regeneration (GTR). The OSSIX® product portfolio has enabled clinicians in hundreds of thousands of procedures in over 40 countries to safely provide predictable, long-term results to their patients over the past 20 years.
Download Material
Whitepaper added to Download Queue
Already in collection
Dentsply Sirona acquires Datum Dental, a leading provider of the innovative OSSIX® regenerative solutions portfolio.
This information and any attachment thereto contains forward-looking information about Dentsply Sirona, Inc.'s financial results, guidance and estimates, business prospects, and products and services that involve substantial risks and uncertainties or other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You can identify these statements by the use of words such as "may," "could," "estimate," "will," "believe," "anticipate," "think," "intend," "expect," "project," "plan," "target," "forecast", and similar words and expressions which identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and involve known and unknown risks and uncertainties, and other factors. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental product and services, pricing, future sales volume of the Company's products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, acquisitions and affiliations, readers are urged to carefully review and consider various disclosures made by the Company in its Annual Report on Form 10-K and in its reports on Forms 10-Q and 8-K filed with the U.S. Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statements contained in this document or the attachments to reflect new information or future events or developments after the date any such statement is made.